Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P06132
UPID:
DCUP_HUMAN
Alternative names:
-
Alternative UPACC:
P06132; A8K762; Q16863; Q16883; Q53YB8; Q53ZP6; Q6IB28; Q9BUZ0
Background:
Uroporphyrinogen decarboxylase plays a pivotal role in the heme biosynthetic pathway, catalyzing the decarboxylation of uroporphyrinogen's acetate side chains to form coproporphyrinogen. This enzyme's activity is crucial for the production of heme, a component vital for oxygen transport and energy production in cells.
Therapeutic significance:
Mutations in uroporphyrinogen decarboxylase are linked to disorders such as Familial porphyria cutanea tarda and Hepatoerythropoietic porphyria, characterized by dermatitis and liver damage. Understanding the enzyme's function could lead to targeted therapies for these porphyrias, offering hope for patients suffering from these conditions.